NCT05610956RecruitingEarly phase 1
Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis
Clinical Study to Evaluate the Possible Efficacy and Safety of Empagliflozin in Patients With Ulcerative Colitis
Source: ClinicalTrials.gov · Last updated 16 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
•This study will be a randomized, controlled, parallel study. .To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 31 Oct 2022
- Start date
- 1 Jan 2023
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Tanta University
- Diseases
- Ulcerative colitis
- NCT number
- NCT05610956
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 60
- From 1 Jan 2023 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other inflammatory bowel diseases (CD).
- History of serious hypersensitivity to empagliflozin or any component of the formulation.
- Chronic urinary tract infection.
- Chronic genital infection.
Lab values
- Severe renal impairment (eGFR \<20 ml/minute/1.73m2) .
Other
- Patients on dialysis.
Who the study is looking for
- •Patients with mild to moderate UC are diagnosed by history, clinical signs according to the Montreal classification of severity of ulcerative colitis and( Endoscopy, and biopsy) to establish the chronicity of inflammation and to exclude other causes of colitis.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gastroenterology and Endoscopy Unit, Internal Medicine Department, Tanta University Hospital. Coordinator of this site? Confirm its status | Tanta | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.